Schwab Charles Investment Management Inc. raised its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 76.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 280,205 shares of the biopharmaceutical company’s stock after buying an additional 121,109 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.62% of Cytokinetics, worth $3,391,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. State of Alaska Department of Revenue acquired a new position in Cytokinetics, during the 2nd quarter valued at about $109,000. Municipal Employees Retirement System of Michigan acquired a new position in Cytokinetics, during the 2nd quarter valued at about $132,000. Bank of America Corp DE increased its stake in Cytokinetics, by 36.8% during the 1st quarter. Bank of America Corp DE now owns 12,571 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 3,383 shares during the period. Parametric Portfolio Associates LLC increased its stake in Cytokinetics, by 1.4% during the 1st quarter. Parametric Portfolio Associates LLC now owns 13,333 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 189 shares during the period. Finally, UBS Group AG increased its stake in Cytokinetics, by 16.9% during the 1st quarter. UBS Group AG now owns 14,281 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 2,060 shares during the period. 71.50% of the stock is currently owned by hedge funds and other institutional investors.

In other news, SVP Bradley Paul Morgan sold 118,330 shares of the company’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $15.00, for a total value of $1,774,950.00. Following the completion of the sale, the senior vice president now directly owns 63,107 shares of the company’s stock, valued at approximately $946,605. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Caryn Gordon Mcdowell sold 13,181 shares of the company’s stock in a transaction dated Friday, October 6th. The shares were sold at an average price of $15.49, for a total value of $204,173.69. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 177,990 shares of company stock valued at $2,628,996. 7.20% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/10/19/cytokinetics-incorporated-cytk-shares-bought-by-schwab-charles-investment-management-inc.html.

Cytokinetics, Incorporated (NASDAQ CYTK) opened at 15.35 on Thursday. The stock has a 50 day moving average of $14.77 and a 200 day moving average of $13.93. Cytokinetics, Incorporated has a 52 week low of $8.77 and a 52 week high of $17.20. The firm’s market cap is $823.77 million.

Cytokinetics, (NASDAQ:CYTK) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.03). The firm had revenue of $3.05 million for the quarter, compared to the consensus estimate of $5.28 million. Cytokinetics, had a negative return on equity of 14.15% and a negative net margin of 16.00%. Analysts anticipate that Cytokinetics, Incorporated will post ($2.51) EPS for the current year.

Several equities analysts have commented on the stock. BidaskClub raised shares of Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Zacks Investment Research cut shares of Cytokinetics, from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. Cantor Fitzgerald reissued a “buy” rating and set a $21.00 target price on shares of Cytokinetics, in a research note on Monday, September 18th. HC Wainwright reissued a “buy” rating and set a $26.00 target price on shares of Cytokinetics, in a research note on Wednesday, September 20th. Finally, ValuEngine raised shares of Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $21.64.

Cytokinetics, Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytokinetics, Incorporated (NASDAQ:CYTK).

Institutional Ownership by Quarter for Cytokinetics, (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.